TNDM logo

TANDEM DIABETES CARE INC

TNDMNASDAQ
πŸ† #1778 by market capEarnings Nov 5US Equity
$118.74β–Ό $3.92 (βˆ’3.30%)
Simulated price
1hβ€”
24hβ–Ό 3.3%
7dβ€”
14dβ€”
30dβ€”
1yβ€”
🏦Market Cap
$1.61B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+7.9%
Slowing
πŸ“ŠGross Margin
56.0%
Healthy
πŸ’΅FCF Margin
-2.6%
Thin
βš–οΈP/S Ratio
1.5x
Cheap
Otter Score
48
Weak
No chart data available for TNDM.

Trading Snapshot

Day Range
$118.19 – $119.82
52-Week Range
$10.25 – $29.65
Volume
$2.57B
Avg Volume
$3.36B
Shares Outstanding
68.5M
Next Earnings
Sep 6, 2026

Fundamentals Snapshot

Annual Revenue
$1.01B
Last Q Revenue
$255M
P/E Ratio
-25.2
P/S Ratio
1.5x
EPS (TTM)
$-0.93
Dividend Yield
0.00%

Why Investors Own TNDM

  • βœ“High-growth profile β€” revenue up +33.1% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 72% gross margin and 27% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$1.01Bβ–² +36.7% YoY
Gross Margin (TTM)
71.6%β–² +3.6% YoY
Operating Income (TTM)
$288Mβ–² +36.7% YoY
Free Cash Flow (TTM)
$269Mβ–² +36.7% YoY

About TANDEM DIABETES CARE INC

Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
48/100

Analyst Price Target

β“˜
Average Target
$130.42
β–² +9.8% Upside
High Target$145.22
Low Target$113.69
Based on 34 analysts

Latest News & Updates